Co-Authors
This is a "connection" page, showing publications co-authored by ANDREW FUTREAL and KANWAL PRATAP SINGH RAGHAV.
Connection Strength
0.311
-
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
Score: 0.198
-
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Res Commun. 2024 May 29; 4(5):1363-1368.
Score: 0.060
-
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
Score: 0.053